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background
A sentinel general practice (GP) 
program for the surveillance of 
influenza-like illness (iLi) has been 
coordinated by the Victorian infectious 
Diseases Reference Laboratory 
(ViDRL) in partnership with the 
Victorian Government Department of 
Health (DH) since 1993. Laboratory 
testing of a sample of iLi cases from 
the surveillance program commenced 
in 1998.1 The program operates 
between May and October each 
year and is approved for continuing 
professional development points 
by the Royal Australian College 
of General Practitioners and the 
Australian College of Rural and 
Remote Medicine. ViDRL also 
monitors diagnoses of iLi made by the 
locum medical practitioners through 
the Melbourne Medical Deputising 
service (MMDs). The DH coordinates 
the surveillance of all laboratory 
confirmed influenza in Victoria, a 
prescribed Group b notifiable disease 
under the Victorian Public Health and 
Wellbeing Act 2008 and Public Health 
and Wellbeing Regulations 2009 for 
which notification is required within 
five days of diagnosis.
The objectives of the influenza 
surveillance system are to:
•	 monitor	the	epidemiology	of	
laboratory confirmed influenza in 
Victoria;
•	 identify	the	onset,	duration	and	
relative severity of annual influenza 
seasons in Victoria;
•	 provide	samples	for	the	
characterisation of circulating 
influenza strains in the community 
to assist in the evaluation of the 
current season; and formulation of 
the following season’s vaccine;
•	 provide	potential	for	early	
recognition of new influenza viruses 
and new or emerging respiratory 
diseases; and
•	 estimate	influenza	vaccine	
effectiveness each year.
in this paper we summarise 
findings from the Victorian influenza 
surveillance system in 2011.
Methods
General practice sentinel 
surveillance
in 2011, 94 GPs (65 from 23 
metropolitan practices and 29 from 
13 rural practices) participated in the 
ViDRL GP sentinel surveillance (GPss) 
program (Figures 1a and 1b). The 
GPss program for 2011 operated from 
2 May to 30 October (weeks 18–43) 
inclusive in which participating GPs 
reported total number of consultations 
per week and age, sex and vaccination 
status of any patients presenting 
with influenza like illness (iLi). GPs 
The influenza surveillance system in Victoria is comprised of several components, including a general practitioner sentinel 
surveillance system, surveillance for influenza-like illness (ILI) in consultations made by the Melbourne Medical Deputising 
Service, laboratory confirmed influenza notified to the Victorian Department of Health and strain typing performed by the 
World Health Organization Collaborating Centre for Reference and Research on Influenza.
As measured by ILI from both the MMDS and GPSS, the 2011 influenza season in Victoria was mild compared to previous 
seasons and was not dominated by any type or subtype of influenza. There were 13 laboratory confirmed influenza 
outbreaks in 2011, nearly all of which were in aged care facilities.
GPs continue to swab more patients, a trend started in 2009, with a significantly lower percent of these testing positive for 
influenza than previous years. The proportion of ILI and swabbed patients who were vaccinated was also significantly lower 
in 2011 than previously. Strain analysis undertaken by the WHO Collaborating Centre indicated a good antigenic match 
between the 2011 vaccine and circulating strains.
The Victorian influenza surveillance system continues to provide a reliable, consistent system for monitoring the epidemiology 
of ILI and laboratory confirmed influenza in Victoria. 
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submitted the data weekly by fax 
or online submission (http://www.
victorianflusurveillance.com.au). A 
case of iLi was defined as fever, cough 
and fatigue/malaise.2 iLi rates were 
calculated as the number of iLi patients 
per 1,000 consultations and compared 
to previously established activity 
thresholds for Victorian influenza 
seasons.3
GPs were requested to collect either 
a nose or throat swab from patients 
presenting within four days of the 
onset of symptoms, chosen at the 
discretion of the GP. Data collected 
on swabbed patients included: 
age, sex, symptoms (fever; cough; 
fatigue; myalgia; other), vaccination 
status (for 2011 and the previous 
2010 vaccine), date of vaccination/s 
and the presence of a co-morbidity 
for which influenza vaccination is 
recommended.4
RnA was extracted from clinical 
specimens and in-house validated  
real-time multiplex PCR assays  
were used to detect type A influenza 
viruses (matrix gene), type b influenza 
viruses (nucleoprotein gene) and type 
C influenza viruses (matrix gene). 
influenza A virus-positive samples were 
sub-typed using individual real-time 
PCR assays incorporating primers and 
probes specific for the haemagglutinin 
gene of A(H1n1)pdm09,5 pre-
pandemic A(H1n1) and A(H3n2) 
strains.
Melbourne medical deputising 
service
The MMDs is the largest medical 
locum service in Australia and has 
contributed to the Victorian influenza 
surveillance system since 2003. The 
MMDs provides a 24-hour medical 
service to patients in their own home 
or aged care facility in the Melbourne 
metropolitan area and Geelong. 
Weekly rates of influenza-related 
diagnoses by MMDs clinicians per 
1,000 consultations were calculated 
from records returned from the 
MMDs clinical database using the 
search terms ‘influenza’ and ‘flu’. To 
avoid inclusion of those immunised 
prophylactically, records that 
contained the terms ‘Fluvax’, ‘at risk’ 
and ‘immunisation’ were excluded 
from the rate calculation.
Notified laboratory confirmed 
influenza
Records of all laboratory confirmed 
influenza cases with a 2011 
notification date were extracted from 
the department’s notifiable infectious 
Diseases surveillance database on 
24 February 2012. For the purposes 
of analysis, ‘routinely notified cases’ 
were those identified by clinical 
presentation, and excluded those 
Figure 1a: Distribution of sentinel surveillance practices in metropolitan 
Victoria, 2011 
Figure 1b: Distribution of sentinel surveillance practices in rural Victoria, 2011
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identified from outbreak investigations 
and the GPss.
Data from the three surveillance 
programs were analysed descriptively 
using Microsoft Excel software. 
The chi squared test was used to 
compare proportions in stata version 
10.0 statistical software, with p<0.05 
considered statistically significant.
Strain typing
A selection of specimens and isolates 
collected in Victoria during 2011 were 
referred to the WHO Collaborating 
Centre for Reference and Research on 
influenza (WHO Collaborating Centre). 
Tissue culture was attempted for all 
of the specimens/isolates received. 
Viruses that were successfully cultured 
were analysed by a haemagglutination 
inhibition assay to determine antigenic 
similarity to the current vaccine strains 
and a neuraminidase inhibition assay to 
determine susceptibility to the antiviral 
drugs oseltamivir and zanamivir. The 
haemagglutinin and neuraminidase 
genes of a selection of specimens and 
isolates were genetically analysed by 
sanger sequencing or pyrosequencing.
Results
General practice sentinel 
surveillance
For the 26 week surveillance period, 
an average of 94 per cent (88/94) 
of GPs submitted tally sheets 
to ViDRL. GPs reported having 
conducted 194,469 consultations 
(135,593 metropolitan and 58,876 
rural) and identified 945 iLi cases 
(769 metropolitan and 176 rural), 
corresponding to metropolitan and 
rural rates across the surveillance 
period of 5.7 and 3.0 iLi cases per 
1,000 consultations respectively.
Among the 945 iLi cases reported by 
GPs, 50 per cent were in females, 47 
per cent in males and the remainder 
unknown. The median age was 
28 years (range one to 88 years). 
Fourteen per cent of iLi cases were 
reported as vaccinated in 2011.
iLi rates during the 2011 season 
generally fell within the range of 
normal seasonal activity, and were low 
compared to previous years (Figure 
2). The overall (metropolitan and rural) 
iLi rate rose above baseline levels 
of 2.5 iLi per 1,000 consultations 
in week 19 (week commencing 9 
May), and declined to baseline levels 
by week 41 (week commencing 10 
October). iLi activity peaked at 10.5 
iLi per 1,000 consultations in week 
32 (week commencing 8 August) in 
metropolitan practices and at 6.2 iLi 
per 1,000 consultations in week 35 
(week commencing 29 August) in rural 
practices (Figure 3).
GPs swabbed a total of 670 (71 per 
cent) iLi patients in 2011, of which 
185 (28 per cent) tested positive to 
influenza. Of these, 102 (55 per cent) 
were type A, 82 (44 per cent) were 
type b and one was type C. Of the 
102 type A influenza viruses detected, 
26 (25 per cent) were A(H1n1)pdm09, 
62 (61 per cent) were A(H3n2) and 
the remaining 14 (14 per cent) were 
not further sub-typed (Table 1).
Among the influenza positive patients, 
164 (86 per cent) were reported as 
not vaccinated (Table 1). Twenty-five 
patients (four influenza positive and 21 
influenza negative) had an unknown 
vaccination status. Overall, 14 per 
cent (92/645) of swabbed patients 
were vaccinated but significantly 
more influenza negative patients were 
Figure 2: General Practice Sentinel Surveillance and Melbourne Medical 
Deputising Service influenza-like illness consultation rates, Victoria, 2003–
2011
Figure 3: General Practice Sentinel Surveillance and Melbourne Medical 
Deputising Service influenza-like illness rates and routinely notified laboratory 
confirmed influenza cases by week, Victoria, 2011
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vaccinated (15 per cent) than influenza 
positive patients (nine per cent; 
p=0.01). There was no significant 
difference in the proportion of patients 
with a co-morbidity recommended for 
influenza vaccination between those 
that were positive for influenza (eight 
per cent) and those that were negative 
(12 per cent; p=0.10).
The median age of influenza A(H1n1)
pdm09 cases detected from the 
GPss was 32 years (range: 1–55 
years), compared to 27 years for 
A(H3n2) (range: 1–72 years) and 14 
years for type b influenza (range: 1–74 
years). The one influenza C case was 
aged 51 years. Forty-three percent 
of GPss influenza positive patients 
were in the 20–49 year age group 
(Figure 4). Fifty-six percent of influenza 
type b cases were younger than 20 
years while 67 per cent of A(H1n1)
pdm09 cases were in the 20–49 years 
age group. There was no statistically 
significant difference in the proportion 
of iLi patients that were swabbed 
across age groups (p=0.23) (Figure 
5). The proportion of patients that 
were vaccinated increased with age, 
particularly those aged 65 years and 
older, while the proportion positive for 
influenza was highest in the 20–49 
years age group.
Notified laboratory confirmed 
influenza
There were 3,007 routinely notified 
cases of influenza made to the 
department in 2011. Of these, 2,184 
(73 per cent) were type A, 787 (26 
per cent) were type b, 34 (1 per cent) 
were type A and b co-infections, and 
two were type C influenza (Table 1). 
The number of cases, particularly 
influenza A, increased from week 
Table 1: Number (%) of General Practice Sentinel Surveillance swabs and routinely notified cases by influenza type/
subtype, vaccination status, co-morbidity and median age, Victoria, 2011
GPSS Routinely notified cases
Total swabs Vaccinated (%) Co-morbidity (%) Median age Total (%) Median age
Influenza A
A(H1n1)pdm09 26  0 (0)  1 (4) 32 213 33
A(H3n2) 62  6 (10)  7 (11) 27 15 44
Untyped 14  3 (21)  0 (0) 2,080
Total influenza A 102  9 (9)  8 8)
Influenza B 82  7 (9)  7 (9) 14 787 20
Influenza A and B co-infection 34
influenza C 1  1 (100)  0 (0) nA 2
negative 485  75 (15)  56 (12) 30
Grand total 670  92 (14)  71 (11) 29 3,007
Figure 4a: Routinely notified cases of laboratory confirmed influenza by age 
group, Victoria, 2011
Figure 4b: GPSS cases of laboratory confirmed influenza by age group, 
Victoria, 2011
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28 (week commencing 18 July) in a 
pattern that was generally consistent 
with GPss and MMDs iLi rates 
(Figure 3). notified cases of both 
type A and type b influenza peaked 
in week 39 (week commencing 19 
september), two weeks and four 
weeks after the peaks in the MMDs 
and the GPss iLi rates respectively.
Of the 2,184 type A cases, 213 (10 
per cent) were A(H1n1)pdm09, 15 
(<1 per cent) were A(H3n2), and 
2,080 (95 per cent) were untyped. 
The median age of routinely notified 
influenza A(H1n1)pdm09 cases was 
33 years (range: 0–88 years), 44 
years for A(H3n2) (range: 3–90 years) 
and 20 years for type b cases (range: 
0–90 years) (Table 1). Fifty-five per 
cent of notified influenza A(H1n1)
pdm09 cases were in the 20–49 
years age group (55 per cent) (Figure 
4). Females comprised 53 per cent of 
the routinely notified cases in 2011.
seven cases were reported to have 
died as a result of their influenza 
infection in 2011. These cases were 
aged 24 to 85 years with a median of 
63 years. With the exception of one 
case, all were due to type A infection, 
of which three were further subtyped: 
two as A(H1n1)pdm09 and one as 
A(H3n2). One death was due to  
type b.
Outbreak investigations
in 2011, a total of 25 respiratory 
outbreaks were notified to the 
department, of which 13 were 
confirmed as caused by influenza. Of 
these, one was in a prison setting, 
and 12 (one type b and 11 type 
A, of which two were subtyped 
as A(H3n2) and one as A(H1n1)
pdm09) were in aged care facilities. 
The first outbreak occurred in week 
3 (week commencing 17 January). 
The remainder of the outbreaks were 
notified between early August and 
early november, with five outbreaks 
notified in september.
Melbourne medical deputising 
service
A total of 757 patients had a recorded 
“flu” or “influenza” diagnosis by the 
MMDs during the 2011 surveillance 
season, corresponding to 0.6 per cent 
of all consultations. iLi activity rose 
sharply in week 31 (week commencing 
18 July) and peaked in week 36 (week 
commencing 5 september) with  
13.8 iLi per 1,000 consultations, two 
weeks after the peak of the GPss iLi 
rate (Figure 3). Like the GPss,  
the peak iLi rate from the MMDs was 
low compared to previous seasons 
(Figure 2). The peak occurred in week 
36 (week commencing 5 september).
Strain typing
Of the 771 specimens and four 
isolates received at the WHO 
Collaborating Centre, 388 (50 per cent) 
yielded an influenza positive isolate 
following cell culture. Of these, 243 
(63 per cent) were type A and 145 (37 
per cent) were type b. Of the influenza 
A viruses, 89 were A(H1n1)pdm09 
(A/California/7/09) strains and 154 
were A(H3n2) viruses. Eighty-eight 
(98 per cent) of the A(H1n1) viruses 
were antigenically similar to the 2011 
vaccine strain A/California/7/2009, 
while 135 (88 per cent) of the A(H3n2) 
strain viruses were similar to the 2011 
vaccine strain A/Perth/16/2009. 
All influenza type b strains except 
one were of the b/Victoria/2/87 
lineage, with 130 (90 per cent) being 
similar to the 2011 vaccine strain b/
brisbane/60/2008. One type b virus 
was from the b/Yamagata/16/88 
lineage. All of the Victorian influenza 
positive isolates were tested for 
susceptibility to the neuraminidase 
inhibitors oseltamivir and zanamivir. 
One of the 89 A(H1n1)pdm09 viruses 
tested (one per cent) was found 
to be oseltamivir resistant due to a 
H275Y mutation in the neuraminidase 
gene. it is unknown if this patient was 
being treated with oseltamivir prior 
to specimen collection. none of the 
A(H3n2) or b viruses were resistant to 
oseltamivir or zanamivir.
Discussion
The 2011 influenza season in 
Victoria, as measured by iLi from 
both the MMDs and GPss, was mild 
compared to previous seasons. The 
season overall was not dominated 
by any type or subtype of influenza, 
although type A cases tended to be 
more common earlier in the season 
and type b in the latter part. There 
were no detections of pre-pandemic 
H1n1 influenza strains, confirming 
Figure 5: General Practice Sentinel Surveillance ILI and swabs by age group, 
vaccination status and percent positive, Victoria, 2011
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that influenza A(H1n1)pdm09 is now 
the seasonal influenza A(H1n1) strain. 
There were 13 laboratory confirmed 
influenza outbreaks in 2011, nearly 
all of which were in aged care 
facilities, and although this represents 
a considerable increase on the six 
reported in 20106 it may be indicative 
of the re-emergence of influenza 
A(H3n2) which is generally associated 
with older age groups.7
in 2011 the proportion of GPss iLi 
cases that were swabbed was 71 
per cent, similar to 2010 (70 per 
cent)6 and 2009 (68 per cent) but 
significantly higher than from 2003 to 
2008 in which 35–50 per cent of iLi 
patients were swabbed (p<0.001).8 
This suggests higher awareness and/
or concern regarding influenza and an 
increase in the ease of testing since 
the 2009 pandemic. However, only 
28 per cent of tests were positive for 
influenza, which was low compared 
to the previous years 2006 to 2010 in 
which the median proportion positive 
was 35 per cent (range: 28–45 per 
cent) (p<0.001).
The proportion of total iLi cases that 
were vaccinated was 14 per cent 
in 2011, significantly lower than the 
average of the years 2006–2010 (18 
per cent, p<0.001).6,9–11 similarly, 
14 per cent of swabbed iLi cases in 
2011 were vaccinated, significantly 
lower than the average of the previous 
five years 2006–2010 (19 per cent, 
p<0.001). This suggests that while 
patients are being tested more, fewer 
are being vaccinated.
As indicated by the median ages 
and age distributions for both GPss 
laboratory confirmed influenza and 
routine notifications, type b influenza 
cases were generally younger than 
type A(H3n2) cases, consistent 
with the typically observed age 
distributions for these influenza 
types.7 The median age of A(H1n1)
pdm09 has risen from 20 years in 
2009, 26 (GPss) and 21 (routine 
notifications) in 2010 to 32 (GPss) 
and 33 (routine notifications) in 
2011. This increase in age was also 
observed in the United Kingdom 
severe influenza surveillance system 
where the median age of A(H1n1)
pdm09 increased from 20 years in 
2009 to 35 years in 2010.12 such 
a shift in the median age of cases 
is not unexpected following the 
emergence of a pandemic influenza 
strain in which higher attack rates 
in younger age groups that have no 
prior immunity are observed during 
the initial outbreak, followed by a 
shift to older age groups as immunity 
increases in the young.13,14
The trivalent influenza vaccine for the 
2011 southern hemisphere season 
contained California/7/2009 (H1n1)-
like virus, A/Perth/16/2009 (H3n2)-
like virus and b/brisbane/60/2008-like 
virus. strain analysis undertaken 
by the WHO Collaborating Centre 
indicated a good antigenic match 
between the 2011 vaccine and 
circulating strains, with 88 per cent 
of the A(H1n1) viruses matching the 
vaccine strain A/California/7/2009, 
88 per cent of the A(H3n2) viruses 
matching the vaccine strain A/
Perth/16/2009 and 90 per cent 
of type b viruses similar to the b/
brisbane/60/2008 strain in the 
vaccine. We have previously shown 
that type- and subtype-stratified 
adjusted vaccine effectiveness 
estimates (A(H1n1)pdm09: 78 per 
cent; A(H3n2): 58 per cent; b: 53 per 
cent) were broadly consistent with a 
good match between vaccine and 
circulating strains.15
in previous years the iLi rate as 
measured by the MMDs has generally 
peaked prior to that of the GPss, 
followed several weeks later by a 
peak in routine notifications. However 
in 2011 GPss iLi rates peaked two 
weeks prior to that of the MMDs. The 
reasons for this are unclear, but may 
be an artefact of a season with low 
or mild iLi activity in which a peak is 
less well defined and exacerbated by 
the non-specific iLi case definition. 
Routine notifications, given the time 
taken for testing and the notification 
to be made to the department peaked 
the latest. The age distribution of 
laboratory confirmed influenza was 
consistent with previous years, with 
a majority of those from the GPss 
comprised of working age adults, 
while there was a higher proportion 
of elderly among the cases routinely 
notified to the department, likely to be 
a reflection of hospitalised influenza 
patients.
The Victorian influenza surveillance 
system continues to provide a reliable, 
consistent system for monitoring the 
epidemiology of iLi and laboratory 
confirmed influenza in Victoria. 
Victorian influenza surveillance system 
reports are available at https://www.
victorianflusurveillance.com.au/
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